Daily Ards Research Analysis
An updated meta-analysis indicates that liberal transfusion thresholds in acute brain injury reduce sepsis risk and improve functional recovery without increasing ARDS. Cohort data link higher IFNλ2 levels to COVID-19 severity, especially in non-obese individuals, while a mechanistic study identifies a USP7–ICAM1–NF-κB endothelial injury axis in pediatric ARDS as a potential therapeutic target.
Summary
An updated meta-analysis indicates that liberal transfusion thresholds in acute brain injury reduce sepsis risk and improve functional recovery without increasing ARDS. Cohort data link higher IFNλ2 levels to COVID-19 severity, especially in non-obese individuals, while a mechanistic study identifies a USP7–ICAM1–NF-κB endothelial injury axis in pediatric ARDS as a potential therapeutic target.
Research Themes
- Transfusion thresholds and infection risk in neurocritical care
- Immune biomarkers (type III interferons), obesity, and COVID-19 severity
- Endothelial inflammatory mechanisms in pediatric ARDS (USP7–ICAM1–NF-κB axis)
Selected Articles
1. Liberal transfusion strategies reduce sepsis risk and improve neurological recovery in acute brain injury: an updated systematic review and meta-analysis.
Across five RCTs (n=2399), restrictive transfusion thresholds increased sepsis/septic shock and worsened 6-month functional outcomes in acute brain injury without affecting ICU or in-hospital mortality, VTE, or ARDS. Liberal thresholds (Hb ≤10–9 g/dL) may be safer in neurocritical care.
Impact: Synthesizes RCT evidence to challenge restrictive transfusion thresholds in neurocritical care, providing outcome-specific risk estimates including ARDS.
Clinical Implications: Consider liberal hemoglobin thresholds in acute brain injury to reduce sepsis risk and improve functional recovery, pending local protocols. ARDS incidence was not increased, supporting safety from a pulmonary standpoint.
Key Findings
- Restrictive transfusion strategy increased sepsis/septic shock risk (RR 1.42; 95% CI 1.08–1.86; p=0.01).
- Restrictive transfusion worsened 6-month functional outcomes (RR 1.13; 95% CI 1.06–1.21; p=0.0003).
- No differences between strategies in ICU mortality, in-hospital mortality, ARDS, or VTE.
Methodological Strengths
- Meta-analysis of five RCTs totaling 2399 participants.
- Prespecified, clinically relevant outcomes; minimal heterogeneity reported.
Limitations
- Heterogeneous ABI etiologies and transfusion thresholds across trials.
- No mortality benefit detected; ARDS outcome neutral.
Future Directions: Conduct large, CONSORT-compliant RCTs focused on infection and neurologic outcomes, exploring individualized transfusion thresholds (e.g., brain oxygenation-guided) and patient subgroups.
PURPOSE: To advocate for a Liberal Transfusion Strategy (LTS) in neurocritical care patients with Acute Brain Injury (ABI) and provide updated evidence for optimizing transfusion thresholds in clinical guidelines. BACKGROUND: Anemia frequently complicates ABI management, often necessitating red blood cell transfusions. However, the optimal hemoglobin (Hb) threshold for transfusion remains controversial. While earlier meta-analyses indicated no significant differences between LTS and restrictive transfusion strategies (RTS), emerging randomized controlled trials (RCTs) emphasize the need for reappraisal within neurocritical care. METHODS: This meta-analysis included five RCTs involving 2399 patients (1,191 LTS; 1208 RTS) with ABI (subarachnoid hemorrhage, traumatic brain injury, or intracerebral hemorrhage). LTS was defined as transfusion at Hb ≤ 10-9 g/dL, and RTS as transfusion at Hb ≤ 7-8 g/dL. Outcomes assessed included sepsis or septic shock, ICU mortality, unfavorable functional outcomes at six months, venous thromboembolism (VTE), acute respiratory distress syndrome (ARDS), and in-hospital mortality. RESULTS: RTS significantly increased the risk of sepsis or septic shock (relative risk [RR]: 1.42; 95% confidence interval [CI] 1.08-1.86; p = 0.01) and unfavorable functional outcomes at six months (RR 1.13; 95% CI 1.06-1.21; p = 0.0003). No significant differences were observed in ICU mortality (RR 1.00; 95% CI 0.84-1.20; p = 0.96), VTE (RR: 0.88; 95% CI 0.56-1.38; p = 0.58), ARDS (RR 1.05; 95% CI 0.69-1.61; p = 0.81), or in-hospital mortality (RR 0.98; 95% CI 0.76-1.26; p = 0.89). Heterogeneity was minimal (I CONCLUSION: LTS demonstrates the potential to enhance safety and functional recovery in ABI patients by mitigating sepsis risk and promoting favorable neurologic outcomes. Further high-powered RCTs are warranted to validate these findings and refine transfusion protocols.
2. Associations between type III interferons, obesity and clinical severity of COVID-19.
In 853 COVID-19 cases (321 with early plasma sampling), IFNλ2—but not IFNλ4 genotype—was independently associated with disease severity. The IFNλ2–severity association was evident in non-obese patients, suggesting obesity may mask this biomarker signal.
Impact: Defines IFNλ2 as an obesity-modulated immune correlate of COVID-19 severity, informing risk stratification for severe disease including ARDS.
Clinical Implications: IFNλ2 may aid early risk stratification for severe COVID-19, particularly in non-obese patients. Integration with clinical factors could refine triage and monitoring for complications such as ARDS.
Key Findings
- IFNλ4 expression (rs368234815-ΔG) was not associated with COVID-19 severity in 853 genotyped cases.
- IFNλ1 and IFNλ2 levels were higher in severe disease; IFNλ2 remained significant after multivariable adjustment (P<0.001).
- The association between higher IFNλ2 and severity was observed only in non-obese individuals (P<0.01) despite higher absolute IFNλ2 levels in obese subjects.
Methodological Strengths
- Large cohort with 853 genotyped cases; IFN measurements in 321 sampled within 10 days of symptom onset.
- Multivariable adjustment including age, sex, ethnicity, and comorbidities (including obesity).
Limitations
- Observational design limits causal inference.
- Biomarker analyses restricted to a subgroup (321/853), raising potential selection bias; timing limited to early illness.
Future Directions: Prospective validation of IFNλ2-guided risk models across BMI strata; mechanistic work to clarify obesity-related modulation of IFNλ2 signaling and its relationship to ARDS development.
INTRODUCTION: Severe COVID-19 is characterized by hyperimmune host responses contributing to airway damage and acute respiratory distress syndrome. Type III interferons (IFN), including IFN lambda 4 (IFNλ4), expressed in individuals harboring the rs368234815-ΔG allele, are implicated in host immune responses to viral infections, including SARS-CoV-2. METHODS: We investigated associations between IFNλ4 expression through genotyping and COVID-19 disease severity in 853 laboratory-confirmed SARS-CoV-2 cases enrolled in the All-Ireland Infectious Diseases Cohort. Additionally, we measured plasma levels of Type I, II and III IFN using quantitative immunoassays along with IFNλ4 expression and COVID-19 disease severity in a sub-group [n=321 (37.6%)] with samples available within 10 days of symptom onset. IFNλ4 was expressed in 382 (44.8%) but expression was not significantly associated with COVID-19 disease severity. RESULTS: Within the sub-group, we found no consistent associations between IFNλ4 expression and circulating IFNs. However, we observed significantly increased expression of IFNλ1 and IFNλ2 in severe COVID-19 (P<0.01), with IFNλ2 remaining significantly associated after adjustment for age, sex, ethnicity, and comorbidities, including obesity (BMI≥30 kg/m2) (P<0.001). Interestingly, although IFNλ2 levels were significantly higher in subjects with obesity, the association between higher IFNλ2 and COVID-19 disease severity was only observed in individuals without obesity (P<0.01). CONCLUSION: These data reveal an important role for IFNλ2 as an immune correlate that predicts COVID-19 disease severity, which may be masked in those with obesity.
3. USP7-Mediated ICAM1 Facilitates Lipopolysaccharide-Induced Human Pulmonary Microvascular Endothelial Cell Injury to Accelerate Pediatric Acute Respiratory Distress Syndrome.
Patient serum and HPMEC models show that USP7 stabilizes ICAM1 via deubiquitination, amplifying NF-κB–dependent apoptosis, inflammation, oxidative stress, and M1 polarization. Silencing ICAM1 or USP7 attenuates LPS-induced endothelial injury, nominating the USP7–ICAM1 axis as a pediatric ARDS target.
Impact: Reveals a deubiquitination mechanism (USP7→ICAM1→NF-κB) driving endothelial injury in pediatric ARDS, expanding therapeutic target space beyond cytokine blockade.
Clinical Implications: USP7 or ICAM1 inhibition could mitigate endothelial injury in pediatric ARDS; translational development would require in vivo validation and safety profiling.
Key Findings
- ICAM1 was upregulated in pediatric ARDS patient serum; ICAM1 knockdown attenuated LPS-induced HPMEC injury.
- USP7 increased ICAM1 protein via deubiquitination, activating NF-κB signaling.
- USP7 overexpression aggravated apoptosis, inflammation, oxidative stress, and M1 macrophage polarization; USP7 knockdown effects were reversed by ICAM1 upregulation.
Methodological Strengths
- Integration of patient serum data with mechanistic in vitro HPMEC models.
- Use of multiple orthogonal assays (CCK-8, EdU, flow cytometry, oxidative/inflammatory kits) and Co-IP confirming USP7–ICAM1 interaction.
Limitations
- Lack of in vivo validation limits translational inference.
- Clinical cohort size and detailed patient characteristics are not provided in the abstract.
Future Directions: Validate the USP7–ICAM1–NF-κB axis in animal models of pediatric ARDS and assess pharmacologic USP7 inhibition for endothelial protection.
BACKGROUND: Intercellular cell adhesion molecule 1 (ICAM1) has been confirmed to be abnormally expressed in acute respiratory distress syndrome (ARDS) patients. However, its role and mechanism in pediatric ARDS process need further revealed. METHODS: Serum samples were selected from pediatric ARDS patients and age-matched healthy individuals. Lipopolysaccharide (LPS)-induced human pulmonary microvascular endothelial cells (HPMECs) were used to mimic ARDS cell models. Cell proliferation and apoptosis were tested by cell counting kit 8 assay, EdU assay, and flow cytometry. Oxidative stress and inflammation were assessed by corresponding kits. M1 macrophage polarization was evaluated via measuring CD86 positive cell rate. The expression levels of ICAM1, ubiquitin-specific peptidase 7 (USP7), and NF-κB pathway-related markers were detected by quantitative real-time PCR and western blot. The interaction between USP7 and ICAM1 was analyzed by Co-IP assay. RESULTS: LPS induced apoptosis, inflammation, oxidative stress, and M1 macrophage polarization, while suppressed proliferation in HPMECs. ICAM1 was upregulated in pediatric ARDS patients, and its knockdown alleviated HPMEC injury induced by LPS. USP7 positively regulated ICAM1 protein expression through deubiquitination. USP7 overexpression aggravated LPS-induced HPMEC apoptosis, inflammation, oxidative stress, and M1 macrophage polarization. Besides, ICAM1 upregulation could eliminate the inhibitory effect of USP7 knockdown on LPS-induced HPMEC injury. In addition, USP7 activated NF-κB pathway by promoting ICAM1 expression. CONCLUSION: USP7-mediated ICAM1 upregulation could promote LPS-induced HPMEC injury by activating NF-κB pathway, which provided a new idea for the treatment of pediatric ARDS.